A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine in Adults and Elderly Subjects

Trial Profile

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine in Adults and Elderly Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2015

At a glance

  • Drugs Influenza A virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors SK Chemicals
  • Most Recent Events

    • 14 May 2015 New trial record
    • 15 Mar 2015 SK Chemicals is in the final stage of this phase III clinical trial for a quadrivalent seasonal influenza vaccine, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top